Erika Cheung Questions Austin Startup Haemanthus
The diagnostic startup faces scrutiny over its leadership's ties to Elizabeth Holmes.
Updated on Oct. 26, 2026 in Startups
Live Poll
Should individuals convicted of corporate fraud be trusted if they launch new businesses after prison?
Erika Cheung has voiced concerns over the Austin-based diagnostic startup Haemanthus, which is led by Billy Evans. The company has publicly stated on X that Evans' partner, Elizabeth Holmes, has zero involvement in the firm.
Why it matters
Cheung, a former Theranos employee, raised these concerns because she believes Holmes has not demonstrated accountability for her past actions. The scrutiny underscores lingering industry sensitivity regarding diagnostic startups founded by individuals linked to prior fraud convictions.
Elizabeth Holmes is currently serving a sentence for defrauding investors, with a scheduled release date of February 22, 2030. Her sentence was reduced to 10 years and 3 months, while she is slated to transition to an Austin halfway house on August 23, 2027.
The players
Erika Cheung
A former employee at Theranos who has become a vocal critic of the startup's historical actions.
Billy Evans
The CEO of the Austin-based diagnostic startup Haemanthus and partner of Elizabeth Holmes.
Haemanthus
An Austin-based diagnostic startup utilizing AI technology.
Elizabeth Holmes
The former CEO of Theranos, convicted of investor fraud in 2022, and partner of Billy Evans.
The details
Haemanthus is an AI-driven diagnostic startup headquartered in Austin, Texas. The firm has publicly distanced itself from Elizabeth Holmes, who was convicted of investor fraud in 2022. Reports from May 2025 suggested Holmes had been providing advice to Evans from prison, prompting public apprehension regarding the startup's governance.
Timeline
2022: Elizabeth Holmes was convicted of defrauding investors.
May 2025: Reports emerged that Holmes was advising Evans from prison.
August 23, 2027: Holmes is scheduled to move to an Austin halfway house.
February 22, 2030: Holmes is scheduled for release from prison.
The Tech Race
The emergence of Haemanthus reflects a high-scrutiny environment for new diagnostic startups following the 2022 conviction of Elizabeth Holmes. Founders with direct links to past industry fraud face heightened demands for transparency regarding corporate leadership and governance.
The startup's public declaration on X clarifies its current governance structure for stakeholders and prospective partners. No specific product releases or diagnostic capabilities have been disclosed by the company at this time.
The takeaway
Public concern highlights how associations with prior industry scandals continue to impact the credibility of new ventures in the medical diagnostics field. Watch for further disclosures regarding the company's internal governance as the 2027 halfway house transition approaches.
Further reading
For more on the local ecosystem, visit our Startups section.
Source note: This article includes information reported by NewsNation.
Live Poll
Should individuals convicted of corporate fraud be trusted if they launch new businesses after prison?
